These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22108726)

  • 41. [Structural and functional stage of the myocardium in different forms of ischemic heart disease].
    Maslovs'kyĭ VIu; Kolesnyk OM
    Lik Sprava; 2006 Dec; (8):34-8. PubMed ID: 17427422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ventricular remodeling after myocardial infarction. Experimental and clinical studies.
    Ertl G; Gaudron P; Hu K
    Basic Res Cardiol; 1993; 88 Suppl 1():125-37. PubMed ID: 8357328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of apoptosis in adverse ventricular remodeling.
    Abbate A; Narula J
    Heart Fail Clin; 2012 Jan; 8(1):79-86. PubMed ID: 22108728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review on CFD simulation in heart with dilated cardiomyopathy and myocardial infarction.
    Chan BT; Lim E; Chee KH; Abu Osman NA
    Comput Biol Med; 2013 May; 43(4):377-85. PubMed ID: 23428371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Remodeling in the ischemic heart: the stepwise progression for heart failure.
    Mill JG; Stefanon I; dos Santos L; Baldo MP
    Braz J Med Biol Res; 2011 Sep; 44(9):890-8. PubMed ID: 21829898
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The fibrosis-cell death axis in heart failure.
    Piek A; de Boer RA; Silljé HH
    Heart Fail Rev; 2016 Mar; 21(2):199-211. PubMed ID: 26883434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model.
    Weber C; Neacsu I; Krautz B; Schlegel P; Sauer S; Raake P; Ritterhoff J; Jungmann A; Remppis AB; Stangassinger M; Koch WJ; Katus HA; Müller OJ; Most P; Pleger ST
    Gene Ther; 2014 Feb; 21(2):131-8. PubMed ID: 24305416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNAs in the development of left ventricular remodeling and postmyocardial infarction heart failure.
    Sygitowicz G; Maciejak-Jastrzębska A; Sitkiewicz D
    Pol Arch Intern Med; 2020 Jan; 130(1):59-65. PubMed ID: 31933487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Left ventricular dilatation and failure post-myocardial infarction: pathophysiology and possible pharmacologic interventions.
    Firth BG; Dunnmon PM
    Cardiovasc Drugs Ther; 1990 Oct; 4(5):1363-74. PubMed ID: 2149059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Left ventricular systolic and diastolic dysfunction in the acute phases of myocardial ischaemia and infarction, and in the later phases of recovery. Function follows morphology.
    Swan HJ
    Eur Heart J; 1993 Jul; 14 Suppl A():48-56. PubMed ID: 8370363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stage B, a pre-cursor of heart failure.
    Cohn JN; Francis GS
    Heart Fail Clin; 2012 Jan; 8(1):xvii-xviii. PubMed ID: 22108736
    [No Abstract]   [Full Text] [Related]  

  • 52. From risk factors to structural heart disease: the role of inflammation.
    Kalogeropoulos AP; Georgiopoulou VV; Butler J
    Heart Fail Clin; 2012 Jan; 8(1):113-23. PubMed ID: 22108731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pathophysiologic process of ventricular remodeling: from infarct to failure.
    Paul S
    Crit Care Nurs Q; 1995 May; 18(1):7-21. PubMed ID: 7719950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction.
    Wilcox JE; Fonarow GC; Ardehali H; Bonow RO; Butler J; Sauer AJ; Epstein SE; Khan SS; Kim RJ; Sabbah HN; Díez J; Gheorghiade M
    JACC Heart Fail; 2015 Sep; 3(9):661-9. PubMed ID: 26362444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanism of heart failure after myocardial infarction.
    Jiang H; Fang T; Cheng Z
    J Int Med Res; 2023 Oct; 51(10):3000605231202573. PubMed ID: 37818767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of late postmyocardial infarction left ventricular remodeling: an update.
    Mookadam F; Moustafa SE
    Curr Heart Fail Rep; 2009 Dec; 6(4):245-53. PubMed ID: 19948093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities.
    Suthahar N; Meijers WC; Silljé HHW; de Boer RA
    Curr Heart Fail Rep; 2017 Aug; 14(4):235-250. PubMed ID: 28707261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.
    Frantz S; Hundertmark MJ; Schulz-Menger J; Bengel FM; Bauersachs J
    Eur Heart J; 2022 Jul; 43(27):2549-2561. PubMed ID: 35511857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of anti-inflammatory drugs and nanoparticle-based drug delivery models in the management of ischemia-induced heart failure.
    Haley KE; Almas T; Shoar S; Shaikh S; Azhar M; Cheema FH; Hameed A
    Biomed Pharmacother; 2021 Oct; 142():112014. PubMed ID: 34391184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PARP inhibition and postinfarction myocardial remodeling.
    Halmosi R; Deres L; Gal R; Eros K; Sumegi B; Toth K
    Int J Cardiol; 2016 Aug; 217 Suppl():S52-9. PubMed ID: 27392900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.